A growing number of companies have been publicizing efforts to improve diversity in their clinical trials, highlighting moves like partnerships with community organizations and locating trial sites in areas where they are more likely to recruit racially and ethnically diverse participants. But looking at trial demographics in a particular therapeutic area highlights the scope of the problem they are trying to address, namely the historical tendency to enroll trial populations that are predominantly white and affluent.
Roche Holding AG’s Genentech division, for example, has been enlisting trial sites for its inclusive research initiative in the field of oncology. At The Atlantic’s Health Equity Summit in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
